Advances in the researches on the biological activities and inhibitors of phosphatidylinositol 3-kinase

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 5, 2014, Pages 673-687

  Tang, Jian Feng ^a,b   Wen, Qing ^a,b   Sun, Jian ^a,b   Zhang, Wei Ming ^a,b   Zhu, Hai Liang ^a,b  

^a Nanjing Institute for Comprehensive Utilization of Wild Plant   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Antitumor agents; Cancer therapy; G protein; Phosphoinositide 3 kinase; PI3K AKT mTOR pathway; Serine threonine kinase akt

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO [2, 3 D] PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; 4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; 4 DIALLYLAMINOMETHYLENE 1, 3, 4, 7, 10, 11, 12, 13, 14, 15, 16, 17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10, 13 DIMETHYL 3, 7, 17 TRIOXO 2 OXACYCLOPENTA [A] PHENANTHREN 11 YL ACETATE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; AP 23841; BUPARLISIB; BYL 719; CALMODULIN INHIBITOR; CANERTINIB; CC 1779; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; G PROTEIN COUPLED RECEPTOR; GEDATOLISIB; GEFITINIB; IDELALISIB; INK 128; KN 309; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PELITINIB; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PILARALISIB; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PX 316; RAPAMYCIN; RIDAFOROLIMUS; SF 1124; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

APOPTOSIS; AUTOPHAGY; BIOLOGICAL ACTIVITY; CANCER CHEMOTHERAPY; CANCER RESEARCH; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; DRUG ACTIVITY; ENZYME STRUCTURE; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84904463395     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113136660367     Document Type: Review

References (118)

1. Jemal, A.; Siegel, R.; Xu, J.Q.; Ward, E. Cancer Statistics. CA Cancer. J. Clin., 2010, 60, 277-300.
2. Andjelkovic, M.; Jones, P.F.; Grossniklaus, U. Developmental regulation of expression and activity of multiple forms of the Drosophila RAC protein kinase. J. Biol. Chem., 1995, 270, 4066-4075.
3. Lynch, D.K.; Ellis, C.A.; Edwards, P.A.; Hiles, I.D. Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism. Oncogene, 1999, 18, 8024-8032.
4. Murthy, S.S.; Tosolini, A.; Taguchi, T.; Testa, J.R. Mapping of AKT3: Encoding a member of the Akt/protein kinase B family; to human and rodent chromosomes by fluorescence in situ hybridization. Cytogenet Cell Genet., 2000, 88, 38-40.
5. Meier, R.; Hemmings, B.A. Regulation of protein kinase B. J. Recept. Signal Transduct. Res., 1999, 19, 121-128.
6. Testa, J.R.; Bellacosa, A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA, 2001, 98, 10983-10985.
7. Fruman, D.A.; Meyers, R.E.; Cantley, L.C. Phosphoinositide kinases. Ann. Rev. Biochem., 1998, 67, 481-507.
8. Engelman, J.A.; Luo, J.; Cantley, L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet., 2006, 7, 606-619.
9. Vanhaesebroeck, B.; Alessi, D.R. The PI3K-PDK1 connection: More than just a road to PKB. Biochem. J., 2000, 346, 561-576.
10. Leevers, S.J.; Vanhaesebroeck, B.; Waterfield, M.D. Signalling through phosphoinositide 3-kinases: The lipids take centre stage. Curr. Opin. Cell Biol., 1999, 11, 219-225.
11. Carpenter, C.L.; Duckworth, B.C.; Auger, K.R.; Cohen, B.; Schaffhausen, B.S.; Cantley, L.C. Purification and characterization of phosphoinositide 3-kinase from rat liver. J. Biol. Chem., 1990, 265, 19704-19711.
12. Cantley, L.C. The phosphoinositide 3-kinase pathway. Science, 2002, 296, 1655-1657.
13. Wymann, M.P.; Marone R. Phosphoinositide 3-kinase in disease: Timing, location, and scaffolding. Curr. Opin. Cell Biol., 2005, 17, 141-149.
14. Alcazar, I.; Marques, M.; Kumar, A. Hirsch, E.; Wymann, M.; Carrera, A.C.; Barber, D.F. Phosphoinositide 3 kinase {gamma} participates in T cell receptor induced T cellactivation. J. Exp. Med., 2007, 204, 2977-2987.
15. Fruman, D.A.; Mauvais-Jarvis, F.; Pollard, D.A.; Yballe, C.M.; Brazil, D.; Bronson, R.T.; Kahn, C.R.; Cantley, L.C. Hypoglycaemia; liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat. Genet., 2000, 26, 379-382.
16. Brachmann S. M.; Yballe C. M.; Innocenti M.; Deane J. A.; Fruman D. A.; Thomas S. M.; Cantley, L.C. Role of phosphoinositide 3-kinase regulatory isoforms in developmentand actin rearrangement. Mol. Cell. Biol., 2005, 25, 2593-2606.
17. Terauchi, Y.; Tsuji, Y.; Satoh, S.; Minoura, H.; Murakami, K.; Okuno, A.; Inukai, K.; Asano, T.; Kaburagi, Y.; Ueki, K.; Nakajima, H.; Hanafusa, T.; Matsuzawa, Y.; Sekihara, H.; Yin, Y.; Barrett, J.C.; Oda, H.; Ishikawa, T.; Akanuma, Y.; Komuro, I.; Suzuki, M.; Yamamura, K.; Kodama, T.; Suzuki, H.; Yamamura, K.; Kodama, T.; Suzuki, H.; Koyasu, S.; Aizawa, S.; Tobe, K.; Fukui, Y.; Yazaki, Y.; Kadowaki, T. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat. Genet., 1999, 21, 230-235.
18. Hirsch, E.; Katanaev, V.L.; Garlanda, C.; Azzolino, O.; Pirola, L.; Silengo, L.; Sozzani, S.; Mantovani, A.; Altruda, F.; Wymann, M. Central role for G proteincoupled phosphoinositide 3-kinase gamma in inflammation. Science, 2000, 287, 1049-1053.
19. Sasaki, T.; Irie-Sasaki, J.; Jones, R.G.; Oliveira-dos-Santos, A.J.; Stanford, W.L.; Bolon, B.; Wakeham, A.; Itie, A.; Bouchard, D.; Kozieradzki, I.; Joza, N.; Mak, T.W.; Ohashi, P.S.; Suzuki, A.; Penninger, J.M. Function of PI3Kgamma in thymocyte development; T-cell activation, and neutrophil migration. Science, 2000; 287; 1040-1046.
20. Djordjevic, S.; Driscoll, P.C. Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases. Trends Biochem. Sci., 2002, 27, 426-432.
21. Amzel, L.M.; Huang, C.H.; Mandelker, D.; Lengauer, C.; Gabelli, S.B.; Vogelstein, B. Structural comparisons of class I phosphoinositide 3-kinases. Nat. Rev. Cancer, 2008, 8, 665-669.
22. Zvelebil, M.J.; Waterfield, M.D.; Shuttleworth, S.J. Structural analysis of PI3-kinase isoforms: Identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors. Arch. Biochem. Biophys., 2008, 477, 404-410.
23. Hawkins, P.T.; Anderson, K.E.; Davidson, K.; Stephens, L.R. Signalling through Class I PI3Ks in mammalian cells. Biochem. Soc. Trans., 2006, 34, 647-662.
24. Walker, E.H.; Perisic, O.; Ried, C.; Stephens, L.; Williams, R.L. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature, 1999, 402, 313-320.
25. Huang, C.H.; Mandelker, D.; Schmidt-Kittler, O.; Samuels, Y.; Velculescu, V.E.; Kinzler, K.W.; Vogelstein, B.; Gabelli, S.B.; Amzel, L.M. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science, 2007, 318, 1744-1748.
26. Domin, J.; Gaidarov, I.; Smith, M.E.; Keen, J.H.; Waterfield, M.D. The class II phosphoinositide 3-kinase PI3K-C2alpha is concentrated in the trans-Golgi network and present in clathrincoated vesicles. J. Biol. Chem., 2000; 275; 11943-11950.
27. Patrucco, E.; Notte, A.; Barberis, L.; Selvetella, G.; Maffei, A.; Brancaccio, M. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and-independent effects. Cell, 2004, 118, 375-387.
28. Suire, S.; Hawkins, P.; Stephens, L. Activation of phosphoinositide 3-kinase gamma by Ras. Curr. Biol., 2002, 12, 1068-1075.
29. Suire, S.; Condliffe, A. M.; Ferguson, G.J.; Ellson, C.D.; Guillou, H.; Davidson, K.; Welch, H.; Coadwell, J.; Turner, M.; Chilvers, E.R.; Hawkins, PT.; Stephens L. Gbetagammas and the Ras binding domain of p110gamma are both important regulators of PI(3)Kgamma signalling in neutrophils. Nat. Cell Biol., 2006, 8, 1303-1309.
30. Brown, R.A.; Ho, L.K.F.; Weber-Hall, S.J.; Shipley, J.M.; Fry, M.J. Identification and cDNA cloning of a novel mammalian C2 domain-containing phosphoinositide 3-kinase, HsC2-PI3K. Biochem. Biophys. Res. Commun., 1997, 233, 537-544.
31. MacDougall, L.K.; Domin, J.; Waterfield, M.D. A family of phosphoinositide 3-kinases in Drosophila identifies a new mediator of signal transduction. Curr. Biol., 1995, 5, 1404-1415.
32. Moltz, L.; Chen, Y. W.; Hirano, M.; Williams, L. T. J. Cpk is a novel class of Drosophila PtdIns 3-kinase containing a C2 domain. Biol. Chem., 1996, 271, 13892-13899.
33. Domin, J.; Pages, F.; Volinia, S.; Rittenhouse, S.E.; Zvelebil, M.J.; Stein, R.C.; Waterfield, M.D. Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem. J., 1997, 326, 139-147.
34. Moltz, L.; Chen, Y.W.; Hirano, M.; Williams, L.T. Cpk is a novel class of Drosophila PtdIns 3-kinase containing a C2 domain. J. Biol. Chem., 1996, 271, 13892-13899.
35. Liu, P.; Cheng, H.; Roberts, T. M.; Zhao, J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov., 2009, 8, 627-644.
36. Courtney, K.D.; Corcoran, R.B.; Engelman, J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol., 2010, 28, 1075-1083.
37. Yarden, Y. Biology of HER2 and its importance in breast cancer. Oncology, 2001, 61, 1-13.
38. Morgensztern, D.; McLeod, H. L. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anti-cancer Drugs, 2005, 16, 797-803.
39. Cortot, A.; Armand, J.P.; Soria, J.C. PI3K-AKT-mTOR pathway inhibitors. Bulletin Du Cancer. 2006, 93, 19-26.
40. Yap, T.A.; Garrett, M.D.; Walton, M.I.; Raynaud, F.; Bono, J.S.; Workman, P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol., 2008, 8, 393-412.
41. LoPiccolo, J.; Blumenthal, G.M.; Bernstein, W.B.; Dennis, P.A. Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations. Drug Resistance Updates, 2008, 11, 32-50.
42. Datta, S.R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 1997, 91, 231-241.
43. Cardone, M.H.; Roy, N.; Stennicke, H.R.; Salvesen, G.S.; Franke, T.F.; Stanbridge, E.; Frisch, S.; Reed, J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science, 1998, 282, 1318-1321.
44. Romashkova, J.A.; Makarov, S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature, 199, 401, 86-90.
45. Bader, A.G.; Kang, S.; Zhao, L.; Vogt, P.K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer, 2005, 5, 921-929.
46. Burgering, B.M.; Medema, R.H. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J. Leukoc. Biol., 2003, 73, 689-701.
47. Liang, J.; Slingerland, J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle, 2003, 2, 339-345.
48. Li, G.; Robinson, G.W.; Lesche, R.; Martinez-Diaz, H.; Jiang, Z.; Rozengurt, N.; Wagner, K. U.; Wu, D.C.; Lane, T.F.; Liu, X.; Hennighausen, L.; Wu, H. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development, 2002, 129, 4159-4170.
49. Toledo, L.M.; Lydon, N.B.; Elbaum, D. The structure-based design of ATP-sitedirected protein kinase inhibitors. Curr. Med. Chem., 1999, 6, 775-805.
50. Engelman, J.A.; Luo, J.; Cantley, L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet., 2006, 7, 606-619.
51. Bai, X.; Ma, D.; Liu, A.; Shen, X.; Wang, Q.J.; Liu, Y.; Jiang, Y. Rheb activates mTOR by antagonizing its endogenous inhibitor: FKBP38. Science, 2007, 318, 977-980.
52. Sonenberg, N.; Pause, A. Signal transduction. Protein synthesis and oncogenesis meet again. Science, 2006, 314, 428-429.
53. Bader, A.G.; Kang, S.; Zhao, L.; Vogt, P.K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer, 2005, 5, 921-929.
54. Stephens, L.; Williams, R.; Hawkins, P. Phosphoinositide 3-kinases as drug targets in cancer. Curr. Opin. Pharmacol., 2005, 5, 357-365.
55. Kang, S.; Denley, A.; Vanhaesebroeck, B.; Vogt, P.K. Oncogenic transformationinduced by the p110beta;-gamma; and-delta isoforms of class I phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. USA, 2006, 103, 1289-1294.
56. Cully, M.; You, H.; Levine, A.J.; Mak, T.W. Beyond PTEN mutations: The PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer, 2006; 6; 184-192.
57. Suzuki, A.; Itami, S.; Ohishi, M.; Hamada, K.; Inoue, T.; Komazawa, N.; Senoo, H.; Sasaki, T.; Takeda, J.; Manabe, M.; Mak, T.W.; Nakano, T. Keratinocyte-specific Pten deficiency results in epidermal hyperplasia; accelerated hair follicle morphogenesis and tumor formation. Cancer Res., 2003, 63, 674-681.
58. Philp, A.J.; Campbell, I.G.; Leet, C.; Vincan, E.; Rockman, S.P.; Whitehead, R.H.; Thomas, R.J.; Phillips, W.A. The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res., 2001, 61, 7426-7429.
59. Luo, J.; Field, S.J.; Lee, J.Y.; Engelman, J.A.; Cantley, L.C. The p85 regulatory subunit of phosphoinositide 3-kinase downregulates IRS-1 signaling via the formation of a sequestration complex. J. Cell Biol., 2005, 170, 455-464.
60. Shekar, S.C.; Wu, H.; Fu, Z.; Yip, S.C.; Nagajyothi, Cahill, S.M.; Girvin, M.E.; Backer, J.M. Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J. Biol. Chem., 2005, 280, 27850-27855.
61. Steck, P.A.; Pershouse, M.A.; Jasser, S.A.; Yung, W.K.; Lin, H.; Ligon, A.H.; Langford, L.A.; Baumgard, M.L.; Hattier, T.; Davis, T.; Frye, C.; Hu, R.; Swedlund, B.; Teng, D.H.; Tavtigian, S.V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet., 1997, 15, 356-362.
62. Davies, H. Hunter, C.; Smith, S.; Stephens, P.; Greenman, P.; Bignell, G.; Teague, J.; Butler, A.; Edkins, S.; Stevens, C.; Parker, A.; O'Meara, S. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res., 2005, 65, 7591-7595.
63. Parsons, D.W.; Wang, T.L.; Samuels, Y.; Bardelli, A.; Cummins, J.M.; DeLong, L.; Silliman, N.; Ptak, J.; Szabo, S.; Willson, J.K.; Markowitz, S.; Kinzler, K.W.; Vogelstein, B.; Lengauer, C.; Velculescu, V. E. Colorectal cancer: Mutations in a signalling pathway. Nature, 2005, 436, 792.
64. Wang, Z.; Shen, D.; Parsons, D.W.; Bardelli, A.; Sager, J.; Szabo, S.; Ptak, J.; Silliman, N.; Peters, B.A.; van der Heijden, M. S.; Parmigiani, G.; Yan, H.; Wang, T. L.; Riggins, G.; Powell, S.M.; Willson, J.K.; Markowitz, S.; Kinzler, K.W.; Vogelstein, B.; Velculescu, V.E. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science, 2004, 304, 1164-1166.
65. Rodriguez-Viciana, P.; Warne, P. H.; Khwaja, A.; Marte, B.M.; Pappin, D.; Das, P.; Waterfield, M. D.; Ridley, A. Downward, J. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell, 1997, 89, 457-467.
66. Nelson, M.A.; Wymer, J.; Clements, N.J. Detection of K-ras gene mutations in non-neoplastic lung tissue andlung cancers. Cancer Lett., 1996, 103, 115-121.
67. Rolitsky, C.D.; Theil, K.S.; McGaughy, V.R.; Copeland, L.J. Niemann, T.H. HER-2/neu amplification and overexpression in endometrial carcinoma. Int. J. Gynecol. Pathol., 1999, 18, 138-143.
68. Sordella, R.; Bell, D. W.; Haber, D.A. Settleman, J. Gefitinibsensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science, 2004, 305, 1163-1167.
69. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y. Mutations of the BRAF gene in human cancer. Nature, 2002, 417, 949-954.
70. Ward, S.G. Finance, P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr. Opin. Pharmacol., 2003, 3, 426-434.
71. West, K.A.; Castillo, S.S.; Dennis, P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat., 2002, 5, 234-248.
72. Kastan, M.B.; Onyekwere, O.; Sidransky, D.; Vogelstein, B.; Craig, R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 1991, 51, 6304-6311.
73. Hu, B.; Gilkes, D.M.; Chen, J. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res., 2007, 67, 8810-8817.
74. Ogawara, Y.; Kishishita, S.; Obata T.; Isazawa, Y.; Suzuki, T.; Tanaka, K.; Masuyama, N.; Gotoh, Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem., 2002, 277, 21843-21850.
75. Mayo, L.D.; Donner, D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad Sci. USA, 2001, 98, 11598-11603.
76. Yu, H.G.; Ai, Y.W.; Yu, L.L.; Zhou, X.D.; Liu, J.; Li, J.H.; Xu, X.M.; Liu, S.; Chen, J.; Liu, F.; Qi, Y.L.; Deng, Q.; Cao, J.; Liu, S.Q.; Luo, H.S.; Yu, J.P. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int. J. Cancer, 2007; 122; 433-443.
77. Clark, A.S.; West, K.; Streicher, S.; Dennis, P. A. Constitutive and inducible Aktactivity promotes resistance to chemotherapy; trastuzumab; or tamoxifen in breast cancer cells. Mol. Cancer Ther., 2002, 1, 707-717.
78. Krystal, G.W.; Sulanke, G.; Litz, J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth; promotes apoptosis; and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol. Cancer Ther., 2002, 1, 913-922.
79. Sausville, E.A.; Elsayed, Y.; Monga, M.; Kim, G. Signal transduction-directed cancer treatments. Ann. Rev. Pharmacol. Toxicol., 2003, 43, 199-231.
80. Brognard, J.; Clark, A.S.; Ni, Y.; Dennis, P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res., 2001, 61, 3986-3997.
81. Bondar, V.M.; Sweeney-Gotsch, B.; Andreeff, M.; Mills, G.B.; McConkey, D.J. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol. Cancer Ther., 2002, 1, 989-997.
82. Furuya, F.; Lu, C.; Willingham, M.C.; Cheng, S.Y. Inhibition of phosphatidylinositol 3' kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis, 2007, 28, 2451-2458.
83. Lin, N.Y.; Beyer, C.; Giessi, A.; Kireva, T.; Scholtysek, C.; Uderhardt, S.; Munoz, L.E.; Dees, C.; Distler, A.; Wirtz, S.; Kronke, G.; Spencer, B.; Distler, O.; Schett, G.; Distler, J.H. Autophagy regulates TNFα-mediated joint destruction in experimental arthritis. Ann. Rheum. Dis., 2013, 72, 761-768.
84. Baehrecke, E.H. Autophagy: Dual roles in life and death? Nat. Rev. Mol. Cell Biol., 2005, 6, 505-510.
85. Debnath, J.; Baehrecke, E.H.; Kroemer, G. Doesautophagy contribute to cell death? Autophagy, 2005, 1, 66-74.
86. Marte, B.M.; Downward, J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem. Sci., 1997, 22, 355-358.
87. Kang, H.Y.; Shiim, D.; Kang, S.S.; Chang, S.I.; Kim, H.Y. Protein kinase B inhibits endostatin-inducedapoptosis in HUVECs. J. Biochem. Mol. Biol., 2006, 39, 97-104.
88. Herbst, R.S. ZD1839: Targeting the epidermal growth factor receptor in cancer therapy. Exp. Opin. Investig. Drugs, 2002, 11, 837-849.
89. Pao, W.; Miller, V.; Zakowski, M.; Doherty, J.; Politi, K.; Sarkaria, I.; Singh, B.; Heelan, R.; Rusch, V.; Fulton, L.; Mardis, E.; Kupfer, D.; Wilson, R.; Kris, M.; Varmus, H. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Nat. Acad. Sci. USA, 2004, 101, 13306-13311.
90. Takimoto, C.H.; Calvo, E. Principles of Oncologic Pharmacotherapy in Pazdur R; Wagman LD; Camphausen KA; Hoskins WJ (Eds). Cancer Management: A Multidisciplinary Approach. 2008; 11 ed.
91. Hidalgo, M.; Siu, L.L.; Nemunaitis, J.; Rizzo, J.; Hammond, L.A.; Takimoto, C.; Eckhardt, S.G.; Tolcher, A.; Britten, C.D.; Denis, L.; Ferrante, K.; Von Hoff, D.D.; Silberman, S.; Rowinsky, E.K. Phase I and pharmacologic study of OSI-774; an epidermal growth factor receptor tyrosine kinase inhibitor; in patients with advanced solid malignancies. J. Clin. Oncol., 2001, 19, 3267-3279.
92. Raymond, E.; Faivre, S.; Armand, J. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs, 2000, 60, 15-23.
93. Moyer, J.D.; Elsa, G.; Barbacci, Kenneth, K.; Iwata, Lee A.; Bruce, B.; Ann, C.; Catherine, D.; Jonathan, D.; Michael, J. M. Induction of Apoptosis and cell cycle arrest by CP-358;774: an Inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res., 1997, 57, 4838-4848.
94. Gabr, A.G.; Goto, H.; Hanibuchi, M.; Ogawa, H.; Kuramoto, T.; Suzuki, M.; Saijo, A.; Kakiuchi, S.; Trung, V.T.; Sakaguchi, S. Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression. Clin. Exp. Metastasis, 2012, 29, 207-216.
95. Furugaki, K.; Iwai, T.; Kondoh, K.; Motiya, Y.; Mori, K. Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers. Oncol. Lett., 2010, 1, 231-235.
96. Torrance, C.J.; Jackson, P.E.; Montgomery, E.; Kinzler, K.W.; Vogelstein, B.; Wissner, A.; Nunes, M.; Frost, P.; Discafani, C.M. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med., 2000, 6, 1024-1028.
97. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 2001, 344, 783-792.
98. Smaill, J.B.; Rewcastle, G.W.; Loo, J.A.; Greis, K.D.; Chan, O.H.; Reyner, E.L.; Lipka, E.; Showalter, H.D.; Vincent, P.W.; Elliott, W.L.; Denny, W.A. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino) quinazoline-and 4-(phenylamino)pyrido3;2-dpyrimidine-6-acrylamides bearing additional solubilizing functions. J. Med. Chem., 2000, 43, 1380-1397.
99. Smaill, J.B.; Rewcastle, G.W.; Loo, J.A.; Greis, K.D.; Chan, O.H.; Reyner, E.L.; Lipka, E.; Showalter, H.D.H.; Vincent, P.W.; Elliott, W.L.; Denny, W.A. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino) quinazoline-and 4-(phenylamino)pyrido[3;2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J. Med. Chem., 2000, 43, 1380-1397.
100. Nelson, J.M.; Fry, D.W. Akt; MAPK (Erk1/2); and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J. Biol. Chem., 2001, 276, 14842-14827.
101. Ako, E.; Yamashita, Y.; Ohira, M.; Yamazaki, M.; Hori, T.; Kubo, N.; Sawada, T.; Hirakawa, K. The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo. Oncol Rep., 2007, 17, 887-893.
102. Robert, F.; Ezekiel, M.P.; Spencer, S.A.; Meredith, R.F.; Bonner, J.A.; Khazaeli, M.B.; Saleh, M.N.; Carey, D.; LoBuglio, A.F.; Wheeler, R.H.; Cooper, M.R.; Waksal, H.W. Phase I study of antiepidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advancedhead and neck cancer. J. Clin. Oncol., 2001, 19, 3234-3243.
103. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 2001, 344, 783-792.
104. Casagrande, F.; Bacqueville, D.; Pillaire, M.J.; Malecaze, F.; Manenti, S.; Breton-Douillon, M.; Darbon, J.M. G1 phase arrest by the phosphatidylinositol 3-kinase inhibitor LY294002 is correlated to up-regulation of p27Kip1 and inhibition of G1 CDKs in choroidal melanoma cells. FEBS Lett., 1998, 422, 385-390.
105. Powis, G.; Bonjouklian, R.; Berggren, M.M.; Gallegos, A.; Abraham, R.; Ashendel, C.; Zalkow, L.; Matter, W.F.; Dodge, J.; Grindey, G. Wortmannin: A potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res., 1994, 54, 2419-2423.
106. Schultz, R.M.; Merriman, R.L.; Andis, S.L.; Bonjouklian, R.; Grindey, G.B.; Rutherford, P.G.; Gallegos, A.; Massey, K.; Powis, G. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor: wortmannin. Anticancer Res., 1995, 15, 1135-1139.
107. Ng, S.S.; Tsao, M.S.; Nicklee, T.; Hedley, D.W. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res., 2001, 7, 3269-3275.
108. Lemke, L.E.; Paine-Murrieta, G.D.; Taylor, C.W.; Powis, G. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase. Cancer Chemother. Pharmacol., 1999, 44, 491-497.
109. Schwecke, T.; Aparicio, J.F.; Molnar, I.; Konig, A.; Khaw, L.E.; Haydock, S.F.; Oliynyk, M.; Caffrey, P.; Cortes, J.; Lester, J.B. The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin. Proc. Natl. Acad. Sci. USA, 1995; 92; 7839-7843.
110. Chan, S. First report: a phase 2 study of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy. Proc. Am. Soc. Clin. Oncol,. 2002, 21, 175.
111. Dudkin, L.; Dilling, M.B.; Cheshire, P.J.; Harwood, F.C.; Hollingshead, M.; Arbuck, S.G.; Travis, R.; Sausville, E.A.; Houghton, P.J. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res., 2001, 7, 1758-1764.
112. Atkins, M.B. A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol., 2002, 21, 36.
113. O'Brien, C.; Wallin, J.J.; Sampath, D.; GuhaThakurta, D.; Savage, H.; Punnoose, E.A.; Guan, J.; Berry, L.; Prior, W.W.; Amler, L.C.; Belvin, M.; Friedman, L.S.; Lackner, M.R. Predictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin. Cancer Res., 2010, 16, 3670-3683.
114. Shi, Y.; Frankel, A.; Radvanyi, L.G.; Penn, L.Z.; Miller, R.G.; Mills, G.B. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res., 1995, 55, 1982-1988.
115. Gibbons, J. The effect of CCI-779; a novel macrolide anti-tumor agent; on the growth of human tumor cells in vitro and in nude mouse xenografts in vivo. Proc. Am. Assoc. Cancer Res., 1999, 40, 2000.
116. Dejan, J.; Jordi, R.; Ana, M.; Gonzalez, A.; Howard, A.; Burris, B.; Jordan, D.; Berlin, M.; Douglas, B.; Markus, B.; Antonin, S.; Nicolas, R.; Cornelia, Q.; Jose, B. Abstract CT-01: BYL719; a next generation PI3K alpha specific inhibitor: Preliminary safety; PK; and efficacy results from the first-in-human study. Cancer Res., 2012, 72, 1538-7445.
117. Mallon, R.; Feldberg, L.R.; Lucas, J.; Chaudhary, I.; Dehnhardt, C.; Santos, E.D.; Chen, Z.; Santos, O.; Ayral-Kaloustian, S.; Venkatesan, A.; Hollander, I. Antitumor efficacy of PKI-587; a highly potent dual PI3K/mTOR kinase inhibitor. Clin. Cancer Res., 2011, 17, 3193-3203.
118. Davies, B.R.; Greenwood, H.; Dudley, P.; Crafter, C.; Yu, D.H.; Zhang, J.; Li, J.; Gao, B.; Ji, Q.; Maynard, J.; Ricketts, S.A.; Cross, D.; Cosulich, S.; Chresta, C.C.; Page, K.; Yates, J.; Lane, C.; Watson, R.; Luke, R.; Ogilvie, D.; Pass, M. Preclinical pharmacology of AZD5363; an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol. Cancer Ther., 2012, 11, 873-887.